Japanese Encephalitis
62
1
2
52
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
36 trials with published results (58%)
Research Maturity
52 completed trials (84% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 62 trials
100.0%
+13.5% vs benchmark
65%
40 trials in Phase 3/4
69%
36 of 52 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 52 completed trials
Clinical Trials (62)
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
Flavivirus Cross-priming Potential of IMOJEV
Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine